Literature DB >> 22015774

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

P Amé-Thomas1, J Le Priol, H Yssel, G Caron, C Pangault, R Jean, N Martin, T Marafioti, P Gaulard, T Lamy, T Fest, G Semana, K Tarte.   

Abstract

Accumulating evidences indicate that the cellular and molecular microenvironment of follicular lymphoma (FL) has a key role in both lymphomagenesis and patient outcome. Malignant FL B cells are found admixed to specific stromal and immune cell subsets, in particular CD4(pos) T cells displaying phenotypic features of follicular helper T cells (T(FH)). The goal of our study was to functionally characterize intratumoral CD4(pos) T cells. We showed that CXCR5(hi)ICOS(hi)CD4(pos) T cells sorted from FL biopsies comprise at least two separate cell populations with distinct genetic and functional features: (i) CD25(pos) follicular regulatory T cells (T(FR)), and (ii) CD25(neg) T(FH) displaying a FL-B cell supportive activity without regulatory functions. Furthermore, despite their strong similarities with tonsil-derived T(FH), purified FL-derived T(FH) displayed a specific gene expression profile including an overexpression of several genes potentially involved directly or indirectly in lymphomagenesis, in particular TNF, LTA, IL4 or CD40LG. Interestingly, we further demonstrated that these two last signals efficiently rescued malignant B cells from spontaneous and rituximab-induced apoptosis. Altogether, our study demonstrates that tumor-infiltrating CD4(pos) T cells are more heterogeneous than previously presumed, and underlines for the first time the crucial role of T(FH) in the complex set of cellular interactions within FL microenvironment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015774      PMCID: PMC3428269          DOI: 10.1038/leu.2011.301

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  51 in total

1.  Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis.

Authors:  Patricia Amé-Thomas; Hélène Maby-El Hajjami; Céline Monvoisin; Rachel Jean; Delphine Monnier; Sylvie Caulet-Maugendre; Thierry Guillaudeux; Thierry Lamy; Thierry Fest; Karin Tarte
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

2.  Germinal center helper T cells are dual functional regulatory cells with suppressive activity to conventional CD4+ T cells.

Authors:  Ekaterina Marinova; Shuhua Han; Biao Zheng
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

3.  Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

Authors:  Annuska M Glas; Laurent Knoops; Leonie Delahaye; Marie José Kersten; Robby E Kibbelaar; Lodewyk A Wessels; Ryan van Laar; J Han J M van Krieken; Joke W Baars; John Raemaekers; Philip M Kluin; Laura J van't Veer; Daphne de Jong
Journal:  J Clin Oncol       Date:  2007-01-02       Impact factor: 44.544

4.  Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells.

Authors:  Roopali Gandhi; Deepak Kumar; Evan J Burns; Meghan Nadeau; Ben Dake; Alice Laroni; Deneen Kozoriz; Howard L Weiner; Francisco J Quintana
Journal:  Nat Immunol       Date:  2010-08-01       Impact factor: 25.606

5.  Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Zhi-Zhang Yang; Anne J Novak; Steven C Ziesmer; Thomas E Witzig; Stephen M Ansell
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

6.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.

Authors:  Joaquim Carreras; Armando Lopez-Guillermo; Bridget C Fox; Lluis Colomo; Antonio Martinez; Giovanna Roncador; Emili Montserrat; Elias Campo; Alison H Banham
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

7.  Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment.

Authors:  Andrew J Clear; Abigail M Lee; Maria Calaminici; Alan G Ramsay; Kelly J Morris; Simon Hallam; Gavin Kelly; Finlay Macdougall; T Andrew Lister; John G Gribben
Journal:  Blood       Date:  2010-04-07       Impact factor: 22.113

8.  Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma.

Authors:  Julie Bruneau; Danielle Canioni; Amédée Renand; Teresa Marafioti; Jennifer C Paterson; Nadine Martin-Garcia; Philippe Gaulard; Marie-Hélène Delfau; Olivier Hermine; Elizabeth Macintyre; Nicole Brousse; Vahid Asnafi
Journal:  Am J Pathol       Date:  2010-06-21       Impact factor: 4.307

9.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.

Authors:  Tomás Alvaro; Marylène Lejeune; Maria-Teresa Salvadó; Carlos Lopez; Joaquín Jaén; Ramón Bosch; Lluis E Pons
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

10.  The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27.

Authors:  Lionel Apetoh; Francisco J Quintana; Caroline Pot; Nicole Joller; Sheng Xiao; Deepak Kumar; Evan J Burns; David H Sherr; Howard L Weiner; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2010-08-01       Impact factor: 25.606

View more
  65 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.

Authors:  Rada Amin; Frédéric Mourcin; Fabrice Uhel; Céline Pangault; Philippe Ruminy; Loic Dupré; Marion Guirriec; Tony Marchand; Thierry Fest; Thierry Lamy; Karin Tarte
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

3.  Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.

Authors:  S M Ahmad; S K Larsen; I M Svane; M H Andersen
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

4.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

Review 5.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

6.  Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.

Authors:  Marie-Hélène Delfau-Larue; Laurence de Leval; Bertrand Joly; Anne Plonquet; Dominique Challine; Marie Parrens; Alain Delmer; Gilles Salles; Franck Morschhauser; Richard Delarue; Pauline Brice; Reda Bouabdallah; Olivier Casasnovas; Hervé Tilly; Philippe Gaulard; Corinne Haioun
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

7.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

8.  Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Authors:  Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

9.  Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

Authors:  Michael Boice; Darin Salloum; Frederic Mourcin; Viraj Sanghvi; Rada Amin; Elisa Oricchio; Man Jiang; Anja Mottok; Nicolas Denis-Lagache; Giovanni Ciriello; Wayne Tam; Julie Teruya-Feldstein; Elisa de Stanchina; Wing C Chan; Sami N Malek; Daisuke Ennishi; Renier J Brentjens; Randy D Gascoyne; Michel Cogné; Karin Tarte; Hans-Guido Wendel
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

Review 10.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.